



First Quarter 2018 Report

April 15, 2018

[Visit our Website](#)

One Test Technology Transfer to 20/20 Completed

Last month, we received **exclusive access to data from over 20,000 individuals screened for cancer over a dozen years** at the Health Check Center affiliated with the Chang Gung Memorial Hospital, the largest and most prestigious medical institution in Taiwan. This data set, and associated machine learning algorithms co-developed with 20/20, are the foundation of *OneTest*, our new test believed to be the first multi-cancer blood test powered by machine learning algorithms built w/ data from tens of thousands of individuals screened in a real-world clinical setting for enhanced reliability.



Data from blood taken from asymptomatic individuals tested **before** they were diagnosed with cancer has been found far more reliable than data from blood taken **after** a patient has been diagnosed with cancer. The later method is the basis of the overwhelming majority of published cancer biomarker studies, which very rarely transition to clinical / commercial use.

OneTest Successfully Debuted @ MD & D.C. Health Expos

In March, we successfully initiated a pre-commercial debut of *OneTest*, our proprietary multi-cancer detection blood test, at Health Expos in Baltimore and Washington, D.C. On-site blood collection was provided, and we clearly demonstrated consumer demand (90 tests ordered) and willingness to self pay.

We expect to have the capability to run *OneTest* in our CLIA certified laboratory in June. In the meantime, we are piloting an array of marketing

initiatives both conventional (selling to doctors) and novel (retail, direct-to-consumer).

For those who earned test vouchers during our recent Equity Crowdfunding campaign, we expect to begin to honor those beginning in June for those who can obtain blood sample collection from their healthcare provider.

www.OneTestforCancer.com



20/20 Selected for Elite Taiwanese Accelerator Program

20/20 was recently selected from among several hundred applicants from around the world for free 6 month co-working space at this facility in Taipei <http://www.garageplus.asia/en>. Garage+ provides introductions to prospective customers, strategic partners and investors. Because of our important relationship with the Chang Gung University Hospital (discussed above), widely respected throughout Taiwan as its largest hospital group, we believe that this nation is an ideal beachhead to kick-start for our commercial activity which will later expand to Greater China and East Asia.



Our Company Voted 3rd Most Valuable by Leading Angel Investor Group

At the March *Angel Capital Expo* hosted by Keiretsu Forum Northwest Region, 20/20 was voted 3rd place for the "Most Valued" Company Award. The selection was made by more than 400 investor members and guests who attended the event, from among the 18 hand-picked emerging growth companies from all over the U.S. and Canada who presented at the Expo.

Based in Seattle, Washington, the Keiretsu Forum's (K4) Northwest Region is part of the broader Keiretsu Forum angel investment network, the largest and most active individual investor community globally. Over 40 of our shareholders are members or affiliates of K4.



The K4 [press release](#) provides further information about this honor.

Reg. A+ Offering Statement Filed with Securities & Exchange Commission

On March 11, 2018 we filed a Form 1-A Offering Circular with the U.S. Securities and Exchange Commission pursuant to Regulation A. Once the Offering is Qualified by the SEC, we will be entitled to raise up to \$50 million per year from either accredited or non-accredited investors and to go public if / when the timing for such a "mini-IPO" seems optimal. This offering would follow our very successful Reg. CF Equity Crowdfunding campaign at the end of 2017, one of the "20 Best of All-time" according to industry monitors.

A copy of our Offering Circular may be downloaded [here](#). Further disclaimers about this potential Offering are provided below.



All Q'4 '17 Equity Crowdfunding Shareholders (via the MicroVentures portal) should expect to receive their stock certificates electronically from our Transfer Agent over the next 10 business days. For questions please contact investors@2020gene.com

Regulation A

20/20 GeneSystems is "testing the waters" under Regulation A of the Securities Act of 1933. The Company will only be able to make sales of securities after the offering statement that it has filed with the Securities and Exchange Commission (SEC) has been "qualified" by the SEC. The information in the offering statement is more complete than the information the company is providing now, and could differ in important ways. You must read offering statement and other the documents filed with the SEC before investing. The Offering Statement may be viewed by using this link

(https://www.sec.gov/Archives/edgar/data/1139685/000121390018002777/f1a2018_2020genesystems.htm)

No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted, and no part of the purchase price can be received until the offering statement on Form 1-A that the Company filed with the SEC is qualified pursuant to the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked without obligation or commitment of any kind, at any time before notice of its acceptance is given after the qualified date. Any person's indication of interest involves no obligation or commitment of any kind.

For more information about Regulation A offerings, including the unique risks associated with these types of offerings, please click on the SEC's investor alert.

Investing in an initial public offering under Regulation A is subject to unique risks, tolerance for volatility, and potential loss of principal, that customers should be aware of prior to making an investment decision.

Forward-Looking Statements

Some of the statements in this document including statements regarding a future offering of the Company's securities under Regulation A, the potential success of any such offering, and the Company's ability to successfully sell and commercialize its cancer diagnostic products, constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "should", "will" and "would" or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in the Form 1-A with the SEC in March 2018, including in "Risk Factors" and elsewhere therein, identify important factors which you should consider in evaluating our forward-looking statements.

Although the forward-looking statements in this document are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results,

performance, achievements, or outcomes. No assurance can be made that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law.

Tel. 240-453-6339

STAY CONNECTED

